Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age

Vaccine

Volumn 33, Issue 23, 2015, Pages 2727-2733

  Avdicova, Mária ^a   Crasta, Priya D ^b   Hardt, Karin ^c   Kovac, Martina ^c  

^a GlaxoSmithKline ^*  (Slovakia)

^b GlaxoSmithKline Pharmaceuticals Ltd   (India)

^c GSK   (Belgium)

Author keywords

DTPa HBV IPV Hib; Hepatitis B; Immune memory; Persistence; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEPATITIS B SURFACE ANTIBODY; RECOMBINANT HEPATITIS B VACCINE; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS-INACTIVATED POLIOVIRUS-HAEMOPHILUS INFLUENZAE B CONJUGATE-HEPATITIS B VACCINE; HAEMOPHILUS VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; POLIOMYELITIS VACCINE; VACCINE;

ANAMNESTIC RESPONSE; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CHILD; DIPHTHERIA; DRUG SAFETY; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; INFANT; PERTUSSIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; TETANUS; TREATMENT RESPONSE; VACCINATION; AGE; BLOOD; FEMALE; HEPATITIS B VIRUS; IMMUNOLOGY; MALE; PROCEDURES;

AGE FACTORS; CHILD; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HAEMOPHILUS VACCINES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNOLOGIC MEMORY; INFANT; MALE; POLIOVIRUS VACCINE, INACTIVATED; VACCINATION; VACCINES, COMBINED;

EID: 84929497694     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.070     Document Type: Article

References (26)

1. Hepatitis B vaccines. Wkly Epidemiol Rec 2009, 84:405-419.
2. Goldstein S.T., Zhou F., Hadler S.C., Bell B.P., Mast E.E., Margolis H.S. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005, 34:1329-1339.
3. Hyams K.C. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995, 20:992-1000.
4. Margolis H.S., Coleman P.J., Brown R.E., Mast E.E., Sheingold S.H., Arevalo J.A. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995, 274:1201-1208.
5. Progress in the control of viral hepatitis: memorandum from a WHO meeting. Bull World Health Organ 1988, 66:443-455.
6. Viral Hepatitis Prevention Board (VHPB) Prevention and control of perinatal hepatitis B virus (HBV) transmission in the WHO European region - a VHPB Symposium Report 2006, Available at http://www.vhpb.org/files/html/Meetings_and_publications/Viral_Hepatitis_Newsletters/VH15n1.pdf. [accessed 23.06.14].
7. Zepp F., Schmitt H.-J., Cleerbout J., Verstraeten T., Schuerman L., Jacquet J.-M. Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines 2009, 8:663-678.
8. National Childhood Vaccination Schedules. Available at [accessed 23.06.14]. http://www.euvac.net/graphics/euvac/vaccination/vaccination.html.
9. Marshall G.S., Happe L.E., Lunacsek O.E., Szymanski M.D., Woods C.R., Zahn M., et al. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J 2007, 26:496-500.
10. Kalies H., Grote V., Verstraeten T., Hessel L., Schmitt H.-J., von Kries R. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 2006, 25:507-512.
11. TM hexa administered at 3, 5 and 11 months of age. Vaccine 2012, 30:2710-2714.
12. Avdicová M., Prikazský V., Hudecková H., Schuerman L., Willems P. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur J Pediatr 2002, 161:581-587.
13. Zinke M., Kappes R., Kindler K., Paulus-Koschik A., Goering U., Disselhoff J., et al. Immune memory to hepatitis B virus in 4-9-year old children vaccinated in infancy with four doses of hexavalent DTPa-HBV-IPV/Hib vaccine. Hum Vaccin 2009, 5:592-598.
14. Heininger U., Sänger R., Jacquet J.-M., Schuerman L. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine 2007, 25:1055-1063.
15. Steiner M., Ramakrishnan G., Gartner B., Van Der Meeren O., Jacquet J.-M., Schuster V. Lasting immune memory against hepatitis B in children after primary immunization with 4 doses of DTPa-HBV-IPV/Hib in the first and 2nd year of life. BMC Infect Dis 2010, 10:9.
16. Van Damme P., Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 2007, 5:79-84.
17. European Consensus Group on Hepatitis B Immunity Are booster immunisations needed for lifelong hepatitis B immunity?. Lancet 2000, 355:561-565.
18. World Health Organisation Core information for the development of immunization policy 2002, WHO/V&B/02.28.
19. Giambi C., Bella A., Barale A., Montù D., Marchisio M., Oddone M., et al. A cohort study to evaluate persistence of hepatitis B immunogenicity after administration of hexavalent vaccines. BMC Infect Dis 2008, 8:100.
20. Zanetti A.R., Romanò L., Giambi C., Pavan A., Carnelli V., Baitelli G., et al. Hepatitis B immune memory in children primed with hexavalent vaccines and given monovalent booster vaccines: an open-label, randomised, controlled, multicentre study. Lancet Infect Dis 2010, 10:755-761.
21. Fitzsimons D., François G., Hall A., McMahon B., Meheus A., Zanetti A., Duval B., et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine 2005, 23:4158-4166.
22. Samandari T., Fiore A.E., Negus S., Williams J.L., Kuhnert W., McMahon B.J., et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007, 120:e373-e381.
23. Poovorawan Y., Chongsrisawat V., Theamboonlers A., Bock H.L., Leyssen M., Jacquet J-M. Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand. Vaccine 2010, 28:730-736.
24. Su F.-H., Cheng S.-H., Li C.-Y., Chen J.-D., Hsiao C.-Y., Chien C.-C., et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 2007, 25:8085-8090.
25. Duval B., Gîlca V., Boulianne N., De Wals P., Massé R., Trudeau G., De Serres G. Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. Pediatr Infect Dis J 2005, 24:213-218.
26. Wang R., Boland G., van Hattum J., de Gast G. Long-term persistence of T cell memory to HBsAg after hepatitis B vaccination. World J Gastroenterol 2004, 10:260-263.